The study for efficacy of teneligliptin in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus

The study for efficacy of teneligliptin in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus - The study for efficacy of teneligliptin in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013048

Enrollment

100

Registered

2014-02-03

Start date

2014-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease/type 2 diabetes mellitus

Interventions

administration of teneligliptin with diet and exercise therapy diet and exercise therapy only (and administration of glimepiride as needed)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The subjects with fatty liver and more than or equal to 30IU/L of ALT 2) The subjects with more than or equal to 6.0% and less than 8.0% of HbA1c

Exclusion criteria

Exclusion criteria: 1) intake more than 20g/day of ethanol 2) HBsAg and/or HCV Ab positive 3) history of hepatic disease, such as autoimmune liver disease, hemochromatosis and Wilson's disease 4) history of diabetes ketosis and/or diabetic coma 5) during pregnancy

Design outcomes

Primary

Measure	Time frame
improvement in liver stiffness	—

Secondary

Measure	Time frame
improvement in physical findings and laboratory data	—

Countries

Japan

Contacts

Public ContactTomoaki Nakajima

Sapporo Kosei General Hospital Department of hepatology

t.nakajima@ja-hokkaidoukouseiren.or.jp011-261-5331

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026